MedTrace Logo

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

NCT06305702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-03-12

No results posted yet for this study

Summary

A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.

Conditions

Interventions

DRUG

inetetamab

8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days

Sponsors & Collaborators

  • Liaoning Cancer Hospital & Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2024-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06305702 on ClinicalTrials.gov